Clinical Trials Browser

Phase 1/2 × Lutetium × 90 days × Clear all

NCT05413850 2026-03-02

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Phase 1/2 Recruiting

Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms